| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 1.692.214 | 473.071 | 725.006 | 1.485.587 | 2.376.989 |
| Total Income - EUR | - | - | - | - | - | 1.680.139 | 471.077 | 706.840 | 1.439.799 | 2.390.155 |
| Total Expenses - EUR | - | - | - | - | - | 1.538.485 | 526.418 | 622.978 | 1.267.526 | 1.749.688 |
| Gross Profit/Loss - EUR | - | - | - | - | - | 141.653 | -55.341 | 83.861 | 172.273 | 640.467 |
| Net Profit/Loss - EUR | - | - | - | - | - | 113.165 | -55.341 | 76.808 | 145.809 | 555.230 |
| Employees | - | - | - | - | - | 5 | 5 | 8 | 8 | 9 |
Check the financial reports for the company - Anisapharm Distribution S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 56.451 | 42.159 | 43.441 | 43.959 | 35.114 |
| Current Assets | - | - | - | - | - | 159.714 | 503.157 | 740.754 | 779.429 | 1.751.072 |
| Inventories | - | - | - | - | - | 4.211 | 212.275 | 629.440 | 188.882 | 741.786 |
| Receivables | - | - | - | - | - | 49.186 | 289.173 | 109.842 | 498.611 | 494.598 |
| Cash | - | - | - | - | - | 106.317 | 1.709 | 1.472 | 91.936 | 514.688 |
| Shareholders Funds | - | - | - | - | - | 113.212 | 56.123 | 133.105 | 278.510 | 828.376 |
| Social Capital | - | - | - | - | - | 48 | 809 | 811 | 809 | 804 |
| Debts | - | - | - | - | - | 103.109 | 545.414 | 707.521 | 546.269 | 962.264 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Anisapharm Distribution S.r.l.